Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiora Pharmaceuticals, Inc. - Common Stock (NQ:KPRX)

3.140 +0.050 (+1.62%)
Streaming Delayed Price Updated: 10:53 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiora Pharmaceuticals, Inc. - Common Stock

MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!
Via AB Newswire
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham... 
Via Newsfile
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and... 
Via Newsfile
Shares of Kiora Pharmaceuticals Inc. (KPRX) Rise to a New 52-Week High
Via Investor Brand Network
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be... 
Via Newsfile
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual... 
Via Newsfile
Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies... 
Via Newsfile
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Stonegate Healthcare Reviews Retinitis Pigmentosa
Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new... 
Via Newsfile
Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.
Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a... 
Via Newsfile
Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, Formerly NASDAQ:EYEG) Investor Notice: Investigation
San Diego, CA -- (SBWIRE) -- 02/15/2022 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares... 
Via SBWire
Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, Formerly NASDAQ:EYEG) Investor Notice: Investigation Announced
San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares... 
Via SBWire
NASDAQ:KPRX, Formerly NASDAQ:EYEG Investor Alert: Investigation over Potential Wrongdoing at Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 12/01/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc f.k.a. EyeGate... 
Via SBWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.